Mark Awad

Dr. Mark Awad is an assistant professor of medicine at Harvard Medical School and clinical director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. He received his undergraduate degree from Harvard University and his MD and PhD degrees from the Johns Hopkins School of Medicine. He completed his residency and chief residency at the Massachusetts General Hospital, and his medical oncology fellowship at the Dana-Farber Cancer Institute before joining the Dana-Farber faculty in 2014. His translational research focus is on identifying biomarkers of response and resistance to targeted therapies and immunotherapies in lung cancer. He is the principal investigator of several clinical trials for patients with thoracic malignancies and collaborates closely with laboratory-based investigators. His research has been published in journals such as the New England Journal of Medicine, the Journal of Clinical Oncology, Cancer Immunology Research, and the Journal of Thoracic Oncology. He is a recipient of the 2015 Young Investigator Award from the American Society of Clinical Oncology (ASCO), the 2015 Young Investigator Award from the International Association for the Society of Lung Cancer (IASLC), the 2017 Career Development Award from Conquer Cancer Foundation of ASCO, and the 2018 and 2020 ALK Positive/LUNGevity Transformational Research and Clinical Trial Awards. Dr. Awad's main area of research is on cancer immunotherapy, vaccine development, cellular therapies, and targeted therapies. He has been working with a number of laboratories to study the genetics and immune microenvironment of lung tumors in order to develop better immune therapies and targeted therapies for patients with cancer.

Clinical Interests

• Immunotherapy
• Lung cancer
• Mesothelioma
• Targeted therapies